Coronary Artery Disease
Tailored treat-to-target strategy feasible vs. high-intensity regimen for CAD
NEW ORLEANS — Among adults with CAD, a treat-to-target LDL strategy of 50 mg/dL to 70 mg/dL was noninferior to a high-intensity statin therapy for the 3-year composite of death, MI, stroke or coronary revascularization, researchers wrote.
Causal AI ‘translates’ CAD polygenic risk score into clinically actionable data
NEW ORLEANS — Causal artificial intelligence used to augment a polygenic risk score for CAD helped estimate how much individual patients must lower their LDL, systolic BP or both to overcome inherited risk for a major coronary event.
Imaging data may predict best responders to evolocumab therapy: YELLOW III
NEW ORLEANS — In adults with stable CAD on maximally tolerated statin therapy, more intensive lipid lowering with evolocumab was associated with favorable coronary plaque characteristics seen on multiple CV imaging modalities, data show.
CABG outperforms PCI in multivessel disease in real-world cohort with ACS
In a real-world cohort of Medicare beneficiaries with ACS and multivessel CAD, CABG conferred lower odds of mortality, readmission and repeat procedures compared with PCI, researchers reported.
CTO lesions tied to in-hospital complications during, after TAVR
Patients who undergo transcatheter aortic valve replacement with concomitant chronic total occlusion lesions experience more periprocedural complications compared with those without CTO, but are not at increased mortality risk, data show.
Data show aspirin has limited role in patients without CAD
Among adults without CAD, the absolute risk for major bleeding with aspirin as primary prevention therapy exceeds the any absolute MI benefits for every level of atherosclerotic CVD risk, data from a meta-analysis show.
RESPECT-EPA
Highly purified eicosapentaenoic acid vs. usual care in Japanese adults with chronic CAD receiving statins.
EHR-based machine learning model yields novel marker for CAD risk, prognosis
An artificial intelligence-derived marker using electronic health records noninvasively quantified plaque burden and mortality risk for adults from two large biobank cohorts, offering an option for more targeted CAD diagnosis, data show.
CAD polygenic risk score may guide statin initiation for younger adults
Biobank data suggest targeted polygenic risk score testing in younger adults with borderline or intermediate clinical risk may be a useful strategy for determining who will benefit most from initiating statin therapy, researchers reported.
‘Possible’ benefit with highly purified EPA to reduce CV risk in CAD with statin therapy
CHICAGO — In Japanese adults with chronic CAD already treated with statin therapy, highly purified eicosapentaenoic acid showed borderline statistical significance in reducing risk for adverse CV events, researchers reported.